Feb 27,2023

New Research from Dario Demonstrates Improved Clinical Outcomes in Two New Studies at the Advanced Technologies and Treatments for Diabetes 2023 Conference

DarioHealth Corp. announced today two new clinical studies presented at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2023, which was held February 22-25 in Berlin. One of the studies demonstrated improved clinical outcomes in users with Type 2 diabetes and provided further analysis to understand the mediating effects of live human coaching and digital interventions across the Dario user journey. The second study demonstrated Dario's ability to reduce hypoglycemic events in older adults with a digital chronic condition management solution.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Dario Appoints Industry Veteran Jon Kaplan to Board

DarioHealth Corp announced today the appointment of Jon Kaplan to serve as a board member effective immediately. He has previously served in advisory board roles at digital health leaders Livongo, Transcarent, Circulation, and Picwell and brings deep knowledge and connections across the health care industry.

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Diabeloop: launch of a multi-country clinical study in adolescents and young adults with T1D – Unannounced Meal Management efficacy key to a better quality of life for people with diabetes

Diabeloop, leader in Automated Insulin Delivery technology, announces the launch of a clinical study in adolescents and young adults with T1D, in France, Belgium and Germany. Main objective is the validation of its hybrid closed-loop system that doesn’t require meal declarations, a major step towards fully automated solutions. The open-label, multicenter, randomized, cross-over, 4 week outpatient study will assess, in real-life conditions, the efficacy of Diabeloop’s integrated solution, embarking an Unannounced Meal Management module. The Automated Insulin Delivery system will also integrate Terumo Corporation’s MEDISAFE WITH patch pump, for the first time since the companies announced extended development and commercial agreements a little over a year ago.

PRODUCT

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023 TOP STORY

Glooko, Sanofi partner on insulin pen connectivity

Glooko announced today that it entered into a partnership with Sanofi to integrate a connected device for insulin pens into its digital platform. SoloSmart, a single-piece, add-on connected device works with Sanofi’s SoloStar and DoubleStar insulin injection pens. It records the insulin dose, date and time of injection. Through this partnership, the company’s can offer data visualization through the Glooko app.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Insulet stock rises on Street-beating Q4, expected Omnipod growth

Insulet (Nasdaq:PODD) shares ticked up today — a day after releasing fourth-quarter results that came in well ahead of the consensus forecast. Shares of PODD were up slightly to $299.29 apiece by midday trading today. The Acton, Massachusetts-based automated insulin technology developer posted profits of $17 million. That amounts to 24¢ per share on sales of $369.7 million for the three months ended Dec. 31, 2022.

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Report: Apple moves forward with glucose monitoring tech

Apple reportedly believes it could shake up the CGM market with non-invasive glucose monitoring through the Apple Watch. Blooomberg reported that the company has a “moonshot-style” project in the works, according to “sources familiar with the matter.” The report said the tech giant still has years ahead in this development of the technology, which wouldn’t penetrate the skin. Bloomberg said Apple aims to use chip-based silicon photonics and optical absorption spectroscopy to measure glucose levels.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Tandem Diabetes Care stock down on Q4 misses

Tandem Diabetes Care (Nasdaq:TNDM) shares are down today on fourth-quarter results that came up shy of the consensus forecast. Shares of TNDM were down more than 6% to $37.28 apiece by midday trading today. Yesterday evening, the San Diego-based automated insulin delivery technology maker posted losses of $15.85 million. That amounts to losses per share of 25¢ on sales of $220.5 million for the three months ended Dec. 31, 2022.

View Analyst & Ambassador Comments
Go to original news
Feb 23,2023

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. today announced that management will present an update on the company at the following upcoming investor conferences: Sean Christensen, Vice President, Finance and Investor Relations, will present on behalf of the company at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 2:45pm (EST), and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the Raymond James 44th Annual Institutional Investors Conference on Tuesday, March 7, 2023 at 3:25pm (EST).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will present an oral presentation describing meal challenge results at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin February 22-25. The data showed that subjects utilizing inhaled Technosphere Insulin (TI) lowered peak glucose levels 30 minutes faster (200 mg/dl at 60 minutes) than subjects utilizing a rapid-acting analogue (RAA) with an Automated Insulin Delivery (AID) system (264 mg/dl at 90 minutes). Subjects utilizing TI also experienced a significantly lower mean PPG from 45 to 120 minutes post-meal.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

New report points to rising out-of-pocket costs for people living with diabetes in Canada

Too many people living with diabetes in Canada are paying increasing costs for prescribed medications, devices, or supplies, according to Diabetes Canada’s new report on diabetes-related out-of-pocket costs. Living with diabetes in Canada continues to be marked by health inequity as out-of-pocket costs are especially acute for lower income groups and people affected by type 2 diabetes. In certain parts of Canada, out-of-pocket costs can be as high as $10,014 per year for people with type 2 diabetes. In certain parts of Canada, out-of-pocket costs can be as high as $18,306 per year for people with type 1 diabetes.

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES